Drucker commented: GLP1 [drugs] have given us so many wonderful results, but tackling these very challenging brain disorders has been disappointing There was a hope that we would see some benefit, and we didnt. From the Alzheimers Drug Discovery Foundation (ADDF), Howard Fillit, MD, emphasized that even negative trials move the field forward, pointing to the need to target the broader pathobiology of Alzheimers and to consider preventive or combination approaches informed by biomarker profiles
Who Benefits Most from B12 Shots
Aging Cell 22 (10), e13970
How much does GHK-Cu cost at Perfect B
Sincerely, Alex Jabr Co-Owner, BodymetRx Kansas City
CAR T-cell and CAR-NK therapies offer antigen specificity and the potential for immunological memory, but face antigen escape, T-cell dysfunction/exhaustion, manufacturing complexity, and risks such as CRS